Promising Glaucoma Pipeline Therapies such as EYEOP1, Latanoprost 0.005%, POLAT-001, Ranibizumab, Mitomycin (MMC), PRM-151, ...

The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024. The Latanoprost ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark's Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). Glenmark’s latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) is ...

Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment.

The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024.

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference ...

Aim To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) ...